Aura Biosciences, Inc. Variable Lease, Cost
Aura Biosciences, Inc. (AURA) reported Variable Lease, Cost of $745.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Aura Biosciences, Inc. variable lease, cost for the quarter ending 2026-06-30 was $745.00K, a 145.07% increase year-over-year.
- Aura Biosciences, Inc. variable lease, cost for the quarter ending 2026-03-31 was $536.00K, a 99.26% increase year-over-year.
- Aura Biosciences, Inc. variable lease, cost for the quarter ending 2025-12-31 was $1.09M, a 289.68% increase year-over-year.
- Aura Biosciences, Inc. variable lease, cost for the quarter ending 2025-09-30 was $296.00K, a 8.82% increase year-over-year.
- Aura Biosciences, Inc. variable lease, cost for fiscal 2025 was $1.96M, a 64.63% increase from fiscal 2024.
- Aura Biosciences, Inc. variable lease, cost for fiscal 2024 was $1.19M, a 35.11% increase from fiscal 2023.
- Aura Biosciences, Inc. variable lease, cost for fiscal 2023 was $883.00K, a 29.81% decline from fiscal 2022.
- Aura Biosciences, Inc. variable lease, cost for fiscal 2022 was $1.26M, a 290.68% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $745.00K 10-Q · filed 2026-08-11 | $1.28M 10-Q · filed 2026-08-11 | $2.38M derived: sum of 3 quarters · filed 2026-08-11 | $2.67M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $536.00K 10-Q · filed 2026-05-11 | $1.63M derived: sum of 2 quarters · filed 2026-05-11 | $1.93M derived: sum of 3 quarters · filed 2026-05-11 | $2.23M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.39M derived: sum of 2 quarters · filed 2026-03-30 | $1.70M derived: sum of 3 quarters · filed 2026-08-11 | $1.96M 10-K · filed 2026-03-30 |
| 2025-09-30 | $296.00K 10-Q · filed 2025-11-13 | $600.00K derived: sum of 2 quarters · filed 2026-08-11 | $869.00K 10-Q · filed 2025-11-13 | $1.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $304.00K 10-Q · filed 2026-08-11 | $573.00K 10-Q · filed 2026-08-11 | $854.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.13M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $269.00K 10-Q · filed 2026-05-11 | $550.00K derived: sum of 2 quarters · filed 2026-05-11 | $822.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.10M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $553.00K derived: sum of 2 quarters · filed 2026-03-30 | $832.00K derived: sum of 3 quarters · filed 2026-03-30 | $1.19M 10-K · filed 2026-03-30 |
| 2024-09-30 | $272.00K 10-Q · filed 2025-11-13 | $551.00K derived: sum of 2 quarters · filed 2025-11-13 | $912.00K 10-Q · filed 2025-11-13 | $1.13M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $279.00K 10-Q · filed 2025-08-13 | $640.00K 10-Q · filed 2025-08-13 | $859.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.08M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $361.00K 10-Q · filed 2025-05-15 | $580.00K derived: sum of 2 quarters · filed 2025-05-15 | $801.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.02M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $219.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $440.00K derived: sum of 2 quarters · filed 2025-03-24 | $657.00K derived: sum of 3 quarters · filed 2025-03-24 | $883.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $221.00K 10-Q · filed 2024-11-12 | $438.00K derived: sum of 2 quarters · filed 2024-11-12 | $664.00K 10-Q · filed 2024-11-12 | $1.10M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $217.00K 10-Q · filed 2024-08-08 | $443.00K 10-Q · filed 2024-08-08 | $881.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.45M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $309.00K 10-Q · filed 2024-05-09 | $664.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.23M derived: sum of 3 quarters · filed 2024-05-09 | $1.39M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $355.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $921.00K derived: sum of 2 quarters · filed 2024-03-27 | $1.08M derived: sum of 3 quarters · filed 2024-03-27 | $1.26M 10-K · filed 2024-03-27 |
| 2022-09-30 | $566.00K 10-Q · filed 2023-11-09 | $727.00K derived: sum of 2 quarters · filed 2023-11-09 | $903.00K 10-Q · filed 2023-11-09 | $992.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $161.00K 10-Q · filed 2023-08-09 | $337.00K 10-Q · filed 2023-08-09 | $426.00K derived: sum of 3 quarters · filed 2023-08-09 | $516.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $176.00K 10-Q · filed 2023-05-11 | $265.00K derived: sum of 2 quarters · filed 2023-05-11 | $355.00K derived: sum of 3 quarters · filed 2023-05-11 | $431.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $179.00K derived: sum of 2 quarters · filed 2023-03-15 | $255.00K derived: sum of 3 quarters · filed 2023-03-15 | $322.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $90.00K 10-Q · filed 2022-11-10 | $166.00K derived: sum of 2 quarters · filed 2022-11-10 | $233.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $76.00K 10-Q · filed 2022-08-11 | $142.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $66.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |